1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Sanofi - ADR

La vocation de Sanofi est d'accompagner celles et ceux confrontés à des difficultés de santé. Entreprise biopharmaceutique mondiale spécialisée dans la santé humaine qui prévient les maladies avec ses vaccins et propose des traitements innovants. Elle accompagne tant ceux qui sont atteints de maladies rares, que les millions de personnes souffrant d'une maladie chronique. Sanofi et ses plus de 100 000 collaborateurs dans 100 pays transforment l'innovation scientifique en solutions de santé partout dans le monde. Sanofi, Empowering Life, donner toute sa force à la vie.
Olivier Brandicourt

54 Rue la Boetie
Paris, Ile De France 75008
Phone: 33153774000


ADOCIA Announces Full Year 2023 Financial Results and Provides a Corporate and Financial Update
Apr 24, 2024 16:06pm

Cash of €13.0m (million) as of December 31, 2023 (€17.4m as of December 31, 2022), including: The signing of an exclusivity agreement with Sanofi on M1Pram and payment of €10m The July 2023 €10m f…

Source:Finanz Nachrichten
Sanofi reportedly lining up banks for consumer products spinoff
Apr 23, 2024 17:32pm

Sanofi (SNY) is reportedly lining up banks for a potential spinoff of its consumer health products division, which could occur as early as Q4. Read more here.

Source:Seeking Alpha
Sanofi succeeds in late-stage trial for blood disorder candidate
Apr 23, 2024 13:44pm

No summary available.

Source:Seeking Alpha
Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia
Apr 23, 2024 05:18am

Sanofi - Aventis Groupe said results from the LUNA 3 phase 3 study showed that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia. The safety profile was consistent with that reported in previous studies. The company will present detailed results of the LUNA 3 phase 3 study at a medical congress later in the current year.

Source:RTT News
Sanofi - Aventis Groupe: Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Apr 23, 2024 05:10am

Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of r…

Source:Finanz Nachrichten
Sanofi''s Zantac settlement is worth $100M, or $25K per claimant: Bloomberg
Apr 22, 2024 18:51pm

… a settlement figure. Sanofi acknowledged the settlement three … Sanofi pulled Zantac off the market in 2019 when an online pharmacy … , Valisure, raised questions about its contents. “ Sanofi … tribunal sided with Sanofi when Boehringer claimed …

Source:EIN News Pharmaceuticals
Sanofi Cuts Jobs in US Vaccines Division as Part of Restructuring
Apr 20, 2024 02:00am

… after Sanofi announced last week that it would divest Amunix Pharmaceuticals , … investor confidence after the pharma in October 2023 dropped … The news sent the pharma ’s shares plummeting 15% … Nine of these investigational drugs are under its innovative …

Source:EIN News Pharmaceuticals
Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals
Apr 19, 2024 15:00pm

Amidst today''s fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating Eli Lilly and Co (NYSE: LLY ) in comparison to its major competitors within the Pharmaceuticals industry. By analyzing critical financial metrics, market position, and growth potential, our objective is to provide valuable insights for investors and offer a deeper understanding of company''s performance in the industry. Eli Lilly and Co Background Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly''s key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology. Company P/E P/B P/S ROE EBITDA (in billions) Gross Profit (in billions) Revenue Growth Eli Lilly and Co 128.61 65.84 19.75 19.91% $3.03 $7.

Sanofi to overhaul US operations of vaccines, cut jobs
Apr 18, 2024 20:38pm

French drugmaker Sanofi said on Thursday it would restructure the U.S. com­mer­cial op­er­a­tions for its vac­cines and cut an undis­closed num­ber of jobs.

Amgen/AstraZeneca''s Asthma Drug Tezspire Vs. Sanofi/Regeneron''s Blockbuster Dupixent - Analyst Gives His Pick
Apr 17, 2024 18:39pm

Tuesday, Amgen Inc (NASDAQ: AMGN ) provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD) . Tezspire is a registered trademark of Amgen and AstraZeneca Plc (NASDAQ: AZN ). Overall, tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17%, although the reduction was not statistically significant, with p=0.1042. More reductions were observed in a prespecified subgroup of patients with baseline eosinophil count (BEC) ≥150 cells/μL (37%). The trend in reduction was greater in a small number of subjects with BEC ≥300 cells/µL. Also Read: Amgen’s Diversified Portfolio To Drive Long-Term Growth, Though Uncertainties Loom, Analyst … Full story available on